Fulcrum Equity Management’s First Trust NYSE Arca Biotechnology Index Fund FBT Stock Holding History

Fulcrum Equity Management’s Portfolio FBT Stock Details FBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,805	Closed	-$264K	–	94
2023 Q3	$264K	Sell	1,805 -810	-31%	-$123K	0.31%	81
2023 Q2	$400K	Buy	+2,615	New	+$408K	0.46%	57
2021 Q2	–	Sell	-30,290	Closed	-$4.86M	–	198
2021 Q1	$4.86M	Buy	+30,290	New	+$5.19M	1.92%	10
2019 Q2	–	Sell	-163,856	Closed	-$24.7M	–	90
2019 Q1	$24.7M	Buy	+163,856	New	+$23.6M	8.49%	5

Other funds holding FBT

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

BFG

Berger Financial Group Plymouth, Minnesota $1.79B AUM 15.72% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Fulcrum Equity Management's FBT Position: Q4 2023 in Review

Fulcrum Equity Management sold out of First Trust NYSE Arca Biotechnology Index Fund (FBT) in Q4 2023, closing a stake of 1,805 shares — an estimated $264K sold.

Fulcrum Equity Management first reported a position in FBT in Q1 2019 and held it in 4 quarters. The position peaked at $24.7M in Q1 2019. 257 funds tracked by Wall St. Rank hold FBT as of Q4 2023.

Fulcrum Equity Management reported no remaining First Trust NYSE Arca Biotechnology Index Fund position as of Q4 2023 after selling out during the quarter.
Fulcrum Equity Management sold 1,805 First Trust NYSE Arca Biotechnology Index Fund shares in Q4 2023, an estimated $264K.
Fulcrum Equity Management first reported a position in First Trust NYSE Arca Biotechnology Index Fund in Q1 2019 and held it in 4 quarters.
Fulcrum Equity Management's First Trust NYSE Arca Biotechnology Index Fund position peaked at $24.7M in Q1 2019.
257 funds tracked by Wall St. Rank held First Trust NYSE Arca Biotechnology Index Fund as of Q4 2023.

Based on Fulcrum Equity Management's 13F filing for Q4 2023, filed 19 Jan 2024.